A phase II study to evaluate the effect of adjuvant chemotherapy using hepatic arterial infusion chemotherapy of 5-fluorouracil plus systemic chemotherapy of gemcitabine after resection of pancreatic cancer

A phase II study to evaluate the effect of adjuvant chemotherapy using hepatic arterial infusion chemotherapy of 5-fluorouracil plus systemic chemotherapy of gemcitabine after resection of pancreatic cancer - A phase II study to evaluate the effect of adjuvant chemotherapy using hepatic arterial 5FU plus systemic gemcitabine after resection of pancreatic cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000549

Enrollment

Registered

2006-12-15

Start date

2006-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

resectable pancreatic cancer

Interventions

adjuvant chemotherapy using hepatic arterial 5FU (1000mg/m2) plus systemic gemcitabine (1000mg/m2) on days 1, 8, 15 every 28 days x 6 courses

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologically proven ductal pancreatic cancer 2) no previous treatment 3) older than 20 4) Karnofsky Performance Status >= 50 5) normally functioning other organs 6) patient informed consent by documentation

Exclusion criteria

Exclusion criteria: 1) interstitial pneumonia, pulmonary fibrosis 2) intractable pleural effusion 3) intractable diabetes mellitus or liver dysfunction 4) distant metastasis 5) other active cancers 6) apparent infection 7) sever postoperative complications 8) active peptic ulcer 9) episode of myocardial infarction within three months 10) mental disorders 11) pregnacy or patient's hope to be pregnant

Design outcomes

Primary

Measure	Time frame
disease-free survival time	—

Secondary

Measure	Time frame
adverse effect, treatment compliance, survival time	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026